Share This Link

Continue acetaminophen and add a fentanyl patch: Fentanyl patches are reserved for severe chronic pain conditions such as cancer-related pain and are inappropriate for acute musculoskeletal injuries. This option introduces significant risks including respiratory depression, sedation, and dependence without addressing inflammation. The patient’s condition is mild-to-moderate and self-limiting, making opioid therapy unnecessary and unsafe.

Continue acetaminophen and add gabapentin (Neurontin): Gabapentin is indicated for neuropathic pain conditions such as diabetic neuropathy and postherpetic neuralgia. The patient’s pain is inflammatory and mechanical in nature due to ligament injury, not nerve dysfunction. Therefore, gabapentin would not treat the underlying pathology and may only contribute adverse effects such as dizziness and sedation.

Increase the dose of acetaminophen to 6 grams per day and continue rest, ice, compression, elevation: Acetaminophen doses above 3 to 4 grams per day significantly increase the risk of hepatotoxicity and potentially life-threatening liver injury. It does not reduce inflammation, meaning it fails to address the primary cause of pain in this injury. While RICE therapy is appropriate, increasing acetaminophen dosage is unsafe and not evidence-based.

Lovastatin (Mevacor): Lovastatin is a first-generation statin that provides low to moderate LDL reduction depending on the dose. It is metabolized by the CYP3A4 pathway, which increases drug interaction risk and limits aggressive dosing. Even at its maximum tolerated doses, it does not achieve the ≥50% LDL reduction required for high-intensity statin therapy.

Simvastatin (Zocor): Simvastatin is a moderately potent statin that can provide moderate-intensity LDL lowering at standard doses. Higher doses increase the risk of myopathy and rhabdomyolysis, limiting its safe use for high-intensity therapy. Due to safety concerns and metabolic interactions via CYP3A4, it is not preferred for achieving sustained high-intensity LDL reduction in high-risk patients.

All of the above: Not all statins are capable of high-intensity LDL reduction, even when dosed at their maximum safe levels. Lovastatin and simvastatin are generally classified as low to moderate-intensity agents and cannot consistently achieve ≥50% LDL reduction. Only certain statins, such as rosuvastatin and atorvastatin, meet high-intensity criteria.

Sertraline (Zoloft): Sertraline is a selective serotonin reuptake inhibitor (SSRI) used primarily for depression, anxiety disorders, and related mood conditions. It has no established efficacy as a smoking cessation aid and does not target nicotine receptors or withdrawal pathways. Although the patient has a history of depression, he is currently stable and engaged in cognitive behavioral therapy. Therefore, sertraline would not provide benefit for tobacco cessation.

Nicotine Inhaler (Nicotrol): Nicotine inhalers are forms of nicotine replacement therapy that provide short-acting relief of cravings by delivering controlled doses of nicotine. However, this patient has already failed multiple over-the-counter nicotine replacement products, suggesting inadequate response to this class. Continuing within the same therapeutic category is unlikely to yield improved outcomes compared to switching to a non-nicotine-based pharmacologic agent.

Bupropion (Zyban): Bupropion is an atypical antidepressant that also acts as a smoking cessation aid by inhibiting norepinephrine and dopamine reuptake. However, it lowers the seizure threshold and may require caution in patients with certain psychiatric histories. Since the patient was recently weaned off antidepressants and is stable in CBT, varenicline is generally more effective as a first-line choice in patients who have failed nicotine replacement therapy.

Prescribe an oral corticosteroid and taper to treat exacerbation: Oral corticosteroids are reserved for moderate to severe asthma exacerbations with significant airflow limitation or failure of inhaled therapy. There is no evidence in this scenario of an acute exacerbation requiring systemic steroids. Escalating therapy without first assessing adherence and inhaler technique may expose the patient to unnecessary systemic side effects such as immunosuppression, weight gain, and adrenal suppression.

Discontinue using the spacer due to age: Spacers are beneficial for patients of all ages, including adolescents, because they improve medication delivery by reducing oropharyngeal deposition and enhancing pulmonary absorption. Removing the spacer may actually worsen drug delivery and reduce therapeutic effectiveness. Age alone is not a valid reason to discontinue spacer use, especially if technique issues are suspected.

Change KJ to GINA Track 2 and prescribe a short acting beta agonist as needed: Switching treatment strategy without first evaluating adherence and inhaler technique is premature. GINA Track adjustments are typically considered after confirming proper use of current therapy and assessing symptom control objectively. In this case, the most likely issue is not medication choice but improper administration, making reassessment of technique the priority.

Withdrawal Syndrome: Withdrawal syndrome occurs when a medication is abruptly reduced or discontinued, leading to symptoms such as dizziness, irritability, flu-like symptoms, and sleep disturbances. It is not associated with autonomic hyperactivity such as sweating, agitation, and confusion seen in this case. Additionally, LS is not stopping antidepressants but overlapping two SSRIs, making withdrawal less likely as the cause of symptoms.

Relapse Syndrome: Relapse syndrome refers to the return of underlying psychiatric symptoms such as depression or anxiety after inadequate treatment or discontinuation of therapy. It typically presents with mood changes, fatigue, and loss of interest rather than acute autonomic instability or confusion. The rapid onset of systemic symptoms like sweating and disorientation is not consistent with a psychiatric relapse pattern.

Discontinuation Syndrome: Antidepressant discontinuation syndrome occurs when SSRIs are abruptly stopped, especially those with shorter half-lives, leading to symptoms such as dizziness, insomnia, irritability, and sensory disturbances. However, LS is currently taking both citalopram and sertraline simultaneously, meaning serotonergic activity is increased rather than withdrawn. This makes discontinuation syndrome inconsistent with her presentation.

Patient has uncontrolled hypertension: Uncontrolled hypertension is not a direct contraindication to metformin use. In fact, patients with diabetes often have comorbid hypertension and may still benefit from metformin therapy. While blood pressure control is important for overall cardiovascular risk reduction, it does not independently increase the risk of metformin-associated lactic acidosis.

Patient has a sulfa allergy: Metformin is not a sulfonamide medication and does not contain sulfa-related chemical structures. Therefore, a sulfa allergy does not confer cross-reactivity or increased risk when using metformin. This allergy is relevant to certain antibiotics and diuretics, but it is not clinically associated with biguanide therapy.

All options are correct: This option is incorrect because only impaired renal function (as suggested by elevated creatinine) is a true contraindication or major caution for metformin use. Uncontrolled hypertension and sulfa allergy do not independently contraindicate metformin therapy. Therefore, not all listed conditions prevent its use.

Ciprofloxacin (Cipro): Ciprofloxacin is a fluoroquinolone antibiotic primarily used for gram-negative infections, including complicated urinary tract infections and certain resistant bacterial infections. It is not recommended for routine pediatric use due to potential adverse effects on cartilage and musculoskeletal development. Additionally, it is unnecessarily broad-spectrum for uncomplicated acute otitis media.

Moxifloxacin (Avelox): Moxifloxacin is a respiratory fluoroquinolone reserved for severe or resistant infections such as pneumonia or complicated sinusitis in adults. It is not indicated for routine pediatric otitis media and carries significant safety concerns in children, including effects on developing cartilage. Its broad-spectrum activity is unnecessary for initial uncomplicated AOM treatment.

Cephalexin (Keflex): Cephalexin is a first-generation cephalosporin effective mainly against gram-positive organisms but has limited efficacy against common AOM pathogens such as Haemophilus influenzae and Moraxella catarrhalis. While sometimes used for skin infections, it is not a preferred first-line agent for acute otitis media. More targeted therapy such as amoxicillin provides better coverage for typical middle ear pathogens.

Amitriptyline (Elavil): Amitriptyline is a tricyclic antidepressant commonly used for migraine prophylaxis due to its ability to modulate serotonin and norepinephrine pathways involved in pain transmission. It does not cause bronchoconstriction and is generally safe in patients with reactive airway disease. Its sedative effects and anticholinergic side effects are the main limiting factors rather than respiratory complications.

Verapamil (Calan): Verapamil is a calcium channel blocker that helps prevent migraines by stabilizing vascular tone and reducing cerebral vasospasm. It is also used in certain cardiac arrhythmias and does not affect bronchial smooth muscle. Therefore, it is considered safe in patients with reactive airway disease and does not pose a risk of bronchospasm.

Divalproex or Valproate (Depakote): Valproate is an anticonvulsant that increases gamma-aminobutyric acid (GABA) levels, helping stabilize neuronal excitability involved in migraine pathophysiology. It does not interact with beta-2 receptors in the lungs and has no bronchoconstrictive effects. Its adverse effects are primarily hepatic and metabolic rather than respiratory.

Methylcellulose (Citrucel): Methylcellulose is a bulk-forming laxative that works by absorbing water in the intestines, increasing stool bulk and promoting peristalsis. However, its onset of action is slower, often requiring 12 to 72 hours for effect. It is more appropriate for long-term regulation of bowel habits rather than immediate relief of constipation.

Psyllium (Metamucil): Psyllium is another bulk-forming laxative derived from natural fiber that increases stool mass and water retention in the intestines. It requires adequate fluid intake and takes 1 to 3 days to produce noticeable bowel movement improvement. It is effective for chronic constipation management but not for rapid relief.

Polycarbophil (Fibercon): Polycarbophil is a synthetic bulk-forming agent that absorbs water to increase stool size and stimulate bowel activity. Its mechanism requires gradual intestinal adjustment, resulting in delayed onset similar to other fiber-based laxatives. It is primarily used for long-term bowel regulation and is not suitable for fast-acting constipation relief.

Fibric acid derivatives (Gemfibrozil): Fibrates primarily lower triglycerides and can modestly increase HDL cholesterol, making them useful in hypertriglyceridemia. Although they are not first-line for LDL reduction, they still have a role in preventing pancreatitis in severe hypertriglyceridemia. Their use has not been completely abandoned, and they remain an option in specific lipid disorders rather than being universally discouraged.

Cholesterol absorption inhibitors (Ezetimibe): Ezetimibe reduces intestinal absorption of cholesterol and is often used as an adjunct to statins to further lower LDL levels. It has demonstrated cardiovascular benefit when combined with statin therapy in high-risk patients. Because of its favorable safety profile and outcome data, it remains an important and recommended lipid-lowering agent.

Bile acid sequestrants (Cholestyramine): Bile acid sequestrants lower LDL cholesterol by binding bile acids in the intestine, leading to increased hepatic conversion of cholesterol into bile acids. They are still used in selected patients, especially when statins are not tolerated or in combination therapy. Although they are less commonly used due to gastrointestinal side effects, they are not associated with increased cardiovascular risk and are still considered an option in treatment guidelines.